These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1024 related items for PubMed ID: 29486779

  • 1. Response criteria in solid tumors (PERCIST/RECIST) and SUVmax in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy.
    Pierson C, Grinchak T, Sokolovic C, Holland B, Parent T, Bowling M, Arastu H, Walker P, Ju A.
    Radiat Oncol; 2018 Feb 27; 13(1):34. PubMed ID: 29486779
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of response to stereotactic body radiation therapy for nonsmall cell lung cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors.
    Han J, Song Q, Guo F, Du R, Fang H, Kang J, Lu Z.
    Nucl Med Commun; 2022 Jun 01; 43(6):717-724. PubMed ID: 35354781
    [Abstract] [Full Text] [Related]

  • 3. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
    Shang J, Ling X, Zhang L, Tang Y, Xiao Z, Cheng Y, Guo B, Gong J, Huang L, Xu H.
    Eur J Nucl Med Mol Imaging; 2016 Oct 01; 43(11):1945-53. PubMed ID: 27236466
    [Abstract] [Full Text] [Related]

  • 4. Impact of pretreatment whole-tumor perfusion computed tomography and 18F-fluorodeoxyglucose positron emission tomography/computed tomography measurements on local control of non-small cell lung cancer treated with stereotactic body radiotherapy.
    Aoki M, Akimoto H, Sato M, Hirose K, Kawaguchi H, Hatayama Y, Seino H, Kakehata S, Tsushima F, Fujita H, Fujita T, Fujioka I, Tanaka M, Miura H, Ono S, Takai Y.
    J Radiat Res; 2016 Sep 01; 57(5):533-540. PubMed ID: 27296251
    [Abstract] [Full Text] [Related]

  • 5. FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer.
    Kohutek ZA, Wu AJ, Zhang Z, Foster A, Din SU, Yorke ED, Downey R, Rosenzweig KE, Weber WA, Rimner A.
    Lung Cancer; 2015 Aug 01; 89(2):115-20. PubMed ID: 26078260
    [Abstract] [Full Text] [Related]

  • 6. Prognostic index score predicts outcome of patients with Stage I non-small cell lung cancer after stereotactic body radiation therapy.
    Shi S, Ye L, Zhao Q, Hu Y, Huang Y, Chen G, Zeng Z, He J.
    Jpn J Clin Oncol; 2019 Apr 01; 49(4):367-372. PubMed ID: 30715411
    [Abstract] [Full Text] [Related]

  • 7. Prognositc significance of SUVmax on pretreatment 18 F-FDG PET/CT in early-stage non-small cell lung cancer treated with stereotactic body radiotherapy: A meta-analysis.
    Dong M, Liu J, Sun X, Xing L.
    J Med Imaging Radiat Oncol; 2017 Oct 01; 61(5):652-659. PubMed ID: 28266166
    [Abstract] [Full Text] [Related]

  • 8. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
    Woody NM, Stephans KL, Marwaha G, Djemil T, Videtic GM.
    Int J Radiat Oncol Biol Phys; 2015 Jun 01; 92(2):325-31. PubMed ID: 25841625
    [Abstract] [Full Text] [Related]

  • 9. Metabolic tumor volume on FDG-PET/CT is a possible prognostic factor for Stage I lung cancer patients treated with stereotactic body radiation therapy: a retrospective clinical study.
    Takahashi N, Yamamoto T, Matsushita H, Sugawara T, Kubozono M, Umezawa R, Ishikawa Y, Kozumi M, Katagiri Y, Tasaka S, Takeda K, Takeda K, Dobashi S, Jingu K.
    J Radiat Res; 2016 Nov 01; 57(6):655-661. PubMed ID: 27422935
    [Abstract] [Full Text] [Related]

  • 10. A SUVmax-based propensity matched analysis of stereotactic body radiotherapy versus surgery in stage I non-small cell lung cancer: unveiling the role of 18F-FDG PET/CT in clinical decision-making.
    Ye L, Xu F, Shi S, Zeng Z, Jin X, Huang Y, Lu C, Gu J, Ge D, He J.
    Clin Transl Oncol; 2018 Aug 01; 20(8):1026-1034. PubMed ID: 29327241
    [Abstract] [Full Text] [Related]

  • 11. Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy.
    Horne ZD, Clump DA, Vargo JA, Shah S, Beriwal S, Burton SA, Quinn AE, Schuchert MJ, Landreneau RJ, Christie NA, Luketich JD, Heron DE.
    Radiat Oncol; 2014 Jan 30; 9():41. PubMed ID: 24479954
    [Abstract] [Full Text] [Related]

  • 12. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.
    Lovinfosse P, Janvary ZL, Coucke P, Jodogne S, Bernard C, Hatt M, Visvikis D, Jansen N, Duysinx B, Hustinx R.
    Eur J Nucl Med Mol Imaging; 2016 Jul 30; 43(8):1453-60. PubMed ID: 26830299
    [Abstract] [Full Text] [Related]

  • 13. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
    Burdick MJ, Stephans KL, Reddy CA, Djemil T, Srinivas SM, Videtic GM.
    Int J Radiat Oncol Biol Phys; 2010 Nov 15; 78(4):1033-9. PubMed ID: 20472359
    [Abstract] [Full Text] [Related]

  • 14. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J, Khalil AA, Hjorthaug K, Frøkiaer J.
    J Med Imaging Radiat Oncol; 2016 Apr 15; 60(2):231-8. PubMed ID: 26678718
    [Abstract] [Full Text] [Related]

  • 15. Pretreatment maximum standardized uptake value on 18F-fluorodeoxyglucose positron emission tomography is a predictor of outcome for stage I non-small cell lung cancer after stereotactic body radiotherapy.
    Tanaka H, Hayashi S, Hoshi H.
    Asia Pac J Clin Oncol; 2016 Mar 15; 12(1):e113-7. PubMed ID: 24176011
    [Abstract] [Full Text] [Related]

  • 16. Stereotactic body radiotherapy for stage I non-small-cell lung cancer using higher doses for larger tumors: results of the second study.
    Miyakawa A, Shibamoto Y, Baba F, Manabe Y, Murai T, Sugie C, Yanagi T, Takaoka T.
    Radiat Oncol; 2017 Sep 11; 12(1):152. PubMed ID: 28893300
    [Abstract] [Full Text] [Related]

  • 17. Pretreatment [18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy: rethinking the role of positron emission tomography in personalizing treatment based on risk status.
    Nair VJ, MacRae R, Sirisegaram A, Pantarotto JR.
    Int J Radiat Oncol Biol Phys; 2014 Feb 01; 88(2):312-8. PubMed ID: 24411602
    [Abstract] [Full Text] [Related]

  • 18. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
    Satoh Y, Onishi H, Nambu A, Araki T.
    Radiology; 2014 Jan 01; 270(1):275-81. PubMed ID: 24029640
    [Abstract] [Full Text] [Related]

  • 19. Impact of pretreatment tumor growth rate on outcome of early-stage lung cancer treated with stereotactic body radiation therapy.
    Atallah S, Cho BC, Allibhai Z, Taremi M, Giuliani M, Le LW, Brade A, Sun A, Bezjak A, Hope AJ.
    Int J Radiat Oncol Biol Phys; 2014 Jul 01; 89(3):532-8. PubMed ID: 24929163
    [Abstract] [Full Text] [Related]

  • 20. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
    Stahl JM, Ross R, Harder EM, Mancini BR, Soulos PR, Finkelstein SE, Shafman TD, Dosoretz AP, Evans SB, Husain ZA, Yu JB, Gross CP, Decker RH.
    Int J Radiat Oncol Biol Phys; 2016 Dec 01; 96(5):1011-1020. PubMed ID: 27869080
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.